JAMES R. KASINGER - 10 Mar 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: General Counsel and Secretary
Signature: /s/ Michael Esposito, attorney-in-fact
Issuer symbol: CRSP
Transactions as of: 10 Mar 2022
Net transactions value: -$146,104
Form type: 4
Filing time: 14 Mar 2022, 18:01:46 UTC
Previous filing: 22 Feb 2022
Next filing: 18 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+2,834	+6.5%		46,539	10 Mar 2022	Direct	F1, F2
transaction	CRSP	Common Shares	Tax liability	$82,642	-1,321	-2.8%	$62.56	45,218	11 Mar 2022	Direct	F3
transaction	CRSP	Common Shares	Options Exercise		+2,250	+5%		47,468	11 Mar 2022	Direct	F1
transaction	CRSP	Common Shares	Tax liability	$63,462	-1,039	-2.2%	$61.08	46,429	14 Mar 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-2,834	-50%		2,833	10 Mar 2022	Common Shares	2,834		Direct	F1, F4
transaction	CRSP	Restricted Stock Units	Options Exercise		-2,250	-25%		6,750	11 Mar 2022	Common Shares	2,250		Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2	Includes 163 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
F3	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F4	This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.
F5	This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.